Evidence map›Paper›PMID 42446619›Full record

ArticleClinical rheumatology2026

Comparative Value of Traditional versus Novel Immune-Inflammatory Indices in Assessing Disease Activity of Sjögren's Disease: A Multicenter Cohort Study.

Yaqi Zhao, Xu Dong, Pingting Yang, Jiuliang Zhao, Wei Bai, Xinping Tian, Wen Zhang, Mengtao Li, Xiaofeng Zeng, Xiaomei Leng

Abstract readMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yaqi Zhao *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Xu Dong *Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Pingting Yang *Department of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
Jiuliang ZhaoDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Wei BaiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Xinping TianDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Wen ZhangDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Mengtao LiDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. mengtao.li@cstar.org.cn.
Xiaofeng ZengDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. zengxfpumc@163.com.
Xiaomei LengDepartment of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. lpumch@126.com.ORCID http://orcid.org/0000-0002-0215-9176

Funding

Chinese Academy of Medical Sciences Initiative for Innovative Medicine 2021-I2M-1-005Chinese Academy of Medical Sciences Initiative for Innovative Medicine 2022-I2M-1-004Chinese Academy of Medical Sciences Initiative for Innovative Medicine 2023-I2M-2-005Key Technologies Research and Development Program of Anhui Province 2017YFC0907605)Key Technologies Research and Development Program of Anhui Province Ministry of ScienceKey Technologies Research and Development Program of Anhui Province Technology (2017YFC0907601National High Level Hospital Clinical Research Funding 2022-PUMCH-B-013National High Level Hospital Clinical Research Funding 2025-PUMCH-D-001
6 · The paper itself

Abstract

backgroundTo evaluate the comparative value of traditional clinical features and novel immune-inflammatory indices in assessing disease activity in primary Sjögren's Disease (SjD), and to construct a robust classification model for moderate-to-severe disease activity using a machine learning approach.

methodsThis cross-sectional study included 18,738 SjD patients from the Chinese Rheumatism Data Center (CRDC) multicenter prospective cohort. Spearman rank correlation and local polynomial regression (LOESS) were used to explore the relationship between systemic inflammatory indices and the EULAR Sjögren's syndrome disease activity index (ESSDAI). To identify moderate-to-severe disease activity (ESSDAI ≥ 5), data were randomly split into training and validation sets (7:3). Classification models were developed using various machine learning techniques.

resultsHigher ESSDAI scores were significantly associated with elevated levels of both traditional markers (ESR, CRP, IgG) and novel composite indices (NLR, CAR, CLR, IBI) (all p < 0.001). However, these indices exhibited only weak-to-moderate linear correlations with ESSDAI and displayed non-linear saturation trends. In multivariable logistic regression, traditional markers remained independent risk factors, whereas all novel composite indices lost statistical significance, yielding a poor validation area under the curve (AUC) of 0.678. Conversely, the XGBoost model demonstrated modestly favorable overall performance Feature importance analysis revealed that patient-reported outcomes, hemoglobin, WBC, age, and IgG were the top contributors to the model, while novel inflammatory indices were completely excluded.

conclusionNovel immune-inflammatory indices lack provide no independent discriminative value for moderate-to-severe SjD activity when adjusted for traditional parameters. The XGBoost machine learning model effectively handles non-linear variables and highlights the core diagnostic importance of patient-reported outcomes (ESSPRI) and traditional clinical features, providing a favorable evaluation tool. Key Points • Correlation analysis showed that traditional markers (ESR, CRP, IgG) and novel indices (NLR, CAR, CLR, IBI) were significantly associated with higher ESSDAI scores but showed weak-to-moderate linear correlations with nonlinear saturation trends. • In multivariable logistic regression, traditional markers remained independent risk factors, whereas novel indices lost significance. • The XGBoost model outperformed logistic regression and random forest, achieving a validation AUC of 0.701. • Feature importance identified patient-reported outcomes, HB, WBC, age, and IgG as top contributors, while novel indices were excluded.

Indexed as

Sjogren's SyndromeAdultBiomarkersBlood SedimentationC-Reactive ProteinCross-Sectional StudiesFemaleHumansImmunoglobulin GInflammationLogistic ModelsMachine LearningMaleMiddle AgedProspective StudiesSeverity of Illness IndexBiomarkersC-Reactive ProteinImmunoglobulin GESSDAIMachine learningRisk assessment modelSjögren’s DiseaseSpearman rank correlation

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.